This is an error from someone who is "late to the party." In fact it was before the last CRL that the FDA indicated that they were interested in seeing Afrezza tested in children as young as 4 yrs old, but I do not believe that the trials for pediatric use have even been enrolled yet. Although management has not mentioned this in awhile, Mann did bring it up during the recent B of A conference.